Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an AI app tame chemo side effects?

NCT ID NCT07826338

Symptom relief Sponsor: Ege University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers test whether an AI-supported mobile app helps breast cancer patients manage chemotherapy symptoms, feel more confident, and enjoy a better quality of life. Seventy women receiving chemotherapy for the first time join the study. Half use the app to report daily symptoms and get personalized advice, while the other half receive standard care. Both groups complete surveys about symptoms, self-efficacy, and quality of life over several chemotherapy cycles.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an AI-supported mobile app for tracking and managing chemotherapy symptoms
What this could lead to
If it works, this could give breast cancer patients a phone-based tool to report symptoms daily and get personalized advice, possibly easing treatment side effects and improving daily life.
What could go wrong
This is a small, single-country study of 70 women, so results may not apply broadly. The app's benefits depend on how well patients use it, and it may not outperform standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged 18 years and older. * Diagnosed with breast cancer. * Patients with Stage 0, I, II, or III breast cancer. * Receiving chemotherapy for the first time. * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1. * In a stable physical and psychological condition that does not interfere with participation in the study. * Able to read and write in Turkish. * Own a smartphone and have sufficient technological skills to use the mobile application. * Willing to participate in the study and able to provide written informed consent. Exclusion Criteria: * Patients diagnosed with a primary cancer other than breast cancer. * Patients with severe comorbid diseases. * Patients receiving concurrent radiotherapy. * Patients diagnosed with inflammatory breast cancer. * Patients using luteinizing hormone-releasing hormone (LHRH) analogs. * Patients with severe cognitive impairment or psychiatric disorders. * Patients who do not have access to a mobile device or internet connection. * Patients who do not have the skills necessary to use the mobile application.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm chemotherapy-induced toxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Chemotherapy side effects

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ege University Hospital, Berna Türek Chemotherapy Center

    RECRUITING

    Izmir, İzmir, 35100+, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.